Results 41 to 50 of about 3,887,212 (164)

Perioperative Outcomes of Patients With Pancreatic Neuroendocrine Neoplasms in the Context of Different Body Composition Phenotypes

World Journal of Surgery, EarlyView.
Pancreatic neuroendocrine neoplasms (pNEN) are rare and heterogeneous tumors with increasing incidence. While surgical resection remains the only curative treatment, perioperative outcomes are influenced by patient‐related risk factors. Recent research highlights body composition (BC) as a prognostic marker in oncological and transplantation surgery ...
Fabiola A. Bechtiger, Mariah Herbrich, Hazem K. A. A. Hassan, Jörg Kaiser, Thomas Hank, Magdalena Lewosinska, Deniz Uluk, Osman Öcal, Nicole D. Hildebrand, Steven WM Olde Damink, Franck Billmann, Zoltan Czigany, Mohammed Al‐Saeedi   +12 more
wiley   +1 more source

Lanreotide, a Somatostatin Analogue, in Advanced Merkel Cell Carcinoma: A Prospective Single‐Arm Phase II Study

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT Background Merkel Cell Carcinoma (MCC) is a rare, aggressive neuroendocrine and epithelial skin cancer. Somatostatin analogues, such as lanreotide, have shown efficacy in managing other neuroendocrine tumors. Retrospective studies suggest that lanreotide may induce partial response or disease stabilization in patients with advanced MCC.
Julie Charles, Aude Belbezier, Stéphane Mouret, Brigitte Dreno, Stéphane Dalle, Céleste Lebbe, Ewa Hainaut‐Wierzbicka, Andreea Stefan, Julie de Quatrebarbes, Olivier Dereure, Ouidad Zehou, Sandrine Mansard, Alain Dupuy, Caroline Dutriaux, Florent Grange, Caroline Gaudy‐Marqueste, Henri Montaudié, Jean‐Philippe Arnault, Yannick Le Corre, Thibault Kervarrec, Jean‐Louis Quesada, Mahtab Samimi, Marie‐Thérèse Leccia, The Group of Cutaneous Oncology of the French Society of Dermatology   +23 more
wiley   +1 more source

Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists

Frontiers in Medicine, 2022
Peptide receptor radionuclide therapy (PRRT) has over the last two decades emerged as a very promising approach to treat neuroendocrine tumors (NETs) with rapidly expanding clinical applications. By chelating a radiometal to a somatostatin receptor (SSTR)
Mengqi Shi, Mengqi Shi, Vivianne Jakobsson, Vivianne Jakobsson, Lukas Greifenstein, Pek-Lan Khong, Pek-Lan Khong, Xiaoyuan Chen, Xiaoyuan Chen, Xiaoyuan Chen, Xiaoyuan Chen, Xiaoyuan Chen, Richard P. Baum, Jingjing Zhang, Jingjing Zhang, Jingjing Zhang   +15 more
doaj   +1 more source

Genomic Evolution and Immune Contexture With Therapeutic Relevance in Pancreatic Neuroendocrine Neoplasms

Cancer Science, Volume 117, Issue 10, Page 2619-2635, October 2026.
Lineage‐dependent immunogenomic landscapes and biologically informed therapy in pancreatic neuroendocrine neoplasms. Pancreatic neuroendocrine neoplasms display lineage‐dependent immunogenomic landscapes, in which genomic alterations, epigenetic states, antigen‐presentation status, immune‐cell infiltration, and suppressive microenvironments co‐evolve ...
Yohei Tabe, Eito Nakagawa, Daisuke Asano, Eriko Katsuta, Daisuke Ban, Shogo Kumagai   +5 more
wiley   +1 more source

Case Report: PRRT in a patient with Zollinger-Ellison syndrome. The management of gastrointestinal complications

Frontiers in Oncology
Zollinger-Ellison Syndrome (ZES) is a rare condition characterized by excessive gastric acid secretion due to gastrin-producing neuroendocrine tumors.
Martina Di Franco, Rexhep Durmo, Maria Liberata Di Paolo, Roberto Giacosa, Elisa Bannò, Valentina Ambrosini, Valentina Ambrosini, Angelina Filice   +7 more
doaj   +1 more source

Achieving objective response in treatment of non-resectable neuroendocrine tumors does not predict longer time to progression compared to achieving stable disease

BMC Cancer, 2020
Background There are several treatment modalities for unresectable neuroendocrine tumors. Traditionally, the aim of these treatments has been to reduce the tumor load; referred to as objective response (OR).
Espen Thiis-Evensen, Amalie Christine Poole, Hong-Thien Thi Nguyen, Jon Sponheim   +3 more
doaj   +1 more source

Controversies in NEN: An ENETS position statement on the role of liver transplantation (LT) in patients with advanced small‐intestinal and pancreatic NETs

Journal of Neuroendocrinology, Volume 38, Issue 10, October 2026.
Abstract Liver transplantation (LT) may offer survival or symptomatic benefit for highly selected patients with advanced, well‐differentiated small‐intestinal or pancreatic neuroendocrine tumours and unresectable liver‐dominant metastases. However, its role remains controversial, as LT is rarely curative, recurrence is common, and benefits must be ...
Peter Stålberg, Mairéad G. McNamara, Simona Grozinsky‐Glasberg, Andreas Pascher, Beata Kos‐Kudla, Timm Denecke, Nehara Begum, Wendy Martin, Stephanie Alband, Clarisse Dromain, Raj Srirajaskanthan, Eric Baudin   +11 more
wiley   +1 more source

Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate

, 2011
Peptide receptor radionuclide therapy (PRRT) is an efficient treatment for gastroenteropancreatic neuroendocrine tumors (GEP NETs), with outstanding overall response rates and survival.
Samer Ezziddin, Tobias Höller, Christian Boy, Sabet, Amir, Guhlke, Stefan, Biersack, Hans-Jürgen, Willinek, Winfried, Hans-Jürgen Biersack, Stefan Guhlke, Ezziddin, Samer, Höller, Tobias, Hojjat Ahmadzadehfar, Yong-Hing, Charlotte J, Boy, Christian, Heinemann, Florian, Ahmadzadehfar, Hojjat, Charlotte J. Yong-Hing, Winfried Willinek, Florian Heinemann, Amir Sabet   +19 more
core   +1 more source

Metachronous occurrence of acute myeloid leukaemia in a case of neuroendocrine tumour

European Journal of Case Reports in Internal Medicine
Haematological neoplasms are rare in patients undergoing peptide receptor radionuclide therapy (PRRT) for neuroendocrine neoplasms, though the long-term effects on bone marrow function remain an area of interest.
Abhinav Menon, Dilip Harindran Vallathol, Deepak Charles, Shagos Nair, Karthika Kundil Veetil, Ashok S. Komaranchath, Arun R. Warrier   +6 more
doaj   +1 more source

Impact of dead time on quantitative 177Lu-SPECT (QSPECT) and kidney dosimetry during PRRT

EJNMMI Physics, 2020
Background Dead time may affect the accuracy of quantitative SPECT (QPSECT), and thus of dosimetry. The aim of this study was to quantify the effect of dead time on 177Lu-QSPECT and renal dosimetry following peptide receptor radionuclide therapy (PRRT ...
Alessandro Desy, Guillaume F. Bouvet, Andrea Frezza, Philippe Després, Jean-Mathieu Beauregard   +4 more
doaj   +1 more source